Skip to content

US · IMUX · BIOTECHNOLOGY

Immunic, Inc. (IMUX) intrinsic value and stock valuation

$6.99as of 2026-11-21 · Mkt cap 194.79M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Immunic, Inc. DCF and intrinsic value

InvestorsCraft values IMUX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from IMUX’s statements →

Immunic, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New York City, NY 10036 imux.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-97.17M
20112025
Free cash flow
-$-85.97M
20112025
Total equity
-$-6.67M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-103.23M-$-98.05M-$-99.22M-$-119.49M-$-91.67M
Net income-$-97.17M-$-100.51M-$-93.61M-$-120.41M-$-92.94M
EPSd-$-62.29M-$-100.51M-$-212.75M-$-376.28M-$-387.25M
Operating cash flow-$-85.81M-$-84.77M-$-70.83M-$-65.14M-$-83.23M
Capital expenditure-$-160K-$-260K-$-330K-$-110K-$-70K
Free cash flow-$-85.97M-$-85.03M-$-71.16M-$-65.26M-$-83.3M
Total assets$24.1M$40.9M$54.3M$127.8M$139.1M
Total debt$680K$1M$1.33M$1.56M$990K
Net debt-$-14.8M-$-34.66M-$-45.34M-$-105.18M-$-85.87M
Total equity-$-6.67M$18.4M$28.9M$113.7M$127.1M
Cash and short-term investments$15.5M$35.7M$46.7M$116.4M$86.9M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$82M$80.1M$83.2M$71.3M$61.1M
Selling, general and administrative expenses$21.3M$18M$16M$15.3M$13.3M
Other expenses$0.00$0.00$0.00$33M$17.3M
Operating expenses$103.2M$98.1M$99.2M$119.5M$91.7M
Cost and expenses$103.2M$98.1M$99.2M$119.5M$91.7M
Interest income$1.04M$3.39M$3.08M$1.04M$70K
Interest expense$0.00$0.00$0.00$1.04M$0.00
Depreciation and amortization$170K$130K$110K$80K$90K
Ebitda-$-97M-$-100.37M-$-93.5M-$-86.44M-$-92.86M
Operating income-$-103.23M-$-98.05M-$-99.22M-$-119.49M-$-91.67M
Total other income/expenses, net$6.06M-$-2.46M$5.61M-$-920K-$-1.28M
Income before tax-$-97.17M-$-100.51M-$-93.61M-$-120.41M-$-92.94M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-97.17M-$-100.51M-$-93.61M-$-120.41M-$-92.94M
Weighted average shares outstanding$1.56M$1M$440K$320K$240K
Weighted average diluted shares outstanding$1.56M$1M$440K$320K$240K
Balance sheet
20252024202320222021
Cash and short-term investments$15.5M$35.7M$46.7M$116.4M$86.9M
Net receivables$4.12M$680K$700K$300K$2.15M
Inventory$0.00$0.00$0.00$5.61M$0.00
Total current assets$22.9M$39.3M$52.5M$125.9M$105M
Property, plant and equipment, net$1.18M$1.54M$1.76M$1.85M$1.1M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$33M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.18M$1.54M$1.76M$1.89M$34.1M
Total assets$24.1M$40.9M$54.3M$127.8M$139.1M
Accounts payable$10.1M$7.85M$5.1M$4.28M$3.5M
Short-term debt$470K$740K$690K$570K$410K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$30.6M$22.2M$24.7M$13.1M$11.4M
Long-term debt$210K$260K$640K$990K$580K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$110K$260K$640K$990K$580K
Capital lease obligations$110K$1M$1.33M$1.56M$990K
Total liabilities$30.7M$22.4M$25.4M$14.1M$12M
Common stock$10K$10K$0.00$0.00$0.00
Retained earnings-$-608.57M-$-511.4M-$-410.89M-$-317.28M-$-196.87M
Accumulated other comprehensive income (loss)$2.65M$4.21M$3.76M$3.04M-$-250K
Total equity-$-6.67M$18.4M$28.9M$113.7M$127.1M
Total investments$0.00$0.00$0.00$9.63M$0.00
Total debt$680K$1M$1.33M$1.56M$990K
Net debt-$-14.8M-$-34.66M-$-45.34M-$-105.18M-$-85.87M
Cash flow statement
20252024202320222021
Net income-$-97.17M-$-100.51M-$-93.61M-$-120.41M-$-92.94M
Depreciation and amortization$170K$130K$110K$80K$90K
Stock-based compensation$8.86M$8.53M$7.1M$7.93M$5.95M
Change in working capital$1.84M$560K$15.1M$9.53M-$-9.28M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.24M$3.15M$820K$800K$180K
Net cash provided by operating activities-$-85.81M-$-84.77M-$-70.83M-$-65.14M-$-83.23M
Investments in property, plant and equipment-$-160K-$-260K-$-330K-$-110K-$-70K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-160K-$-260K$9.46M-$-9.74M-$-70K
Common stock issued$65.6M$190K$850K$39.6M$42.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$65.6M$74.5M$1.03M$95.8M$42.8M
Net change in cash-$-20.18M-$-11.01M-$-60.07M$19.9M-$-40.59M
Cash at end of period$15.5M$35.7M$46.7M$106.8M$86.9M
Operating cash flow-$-85.81M-$-84.77M-$-70.83M-$-65.14M-$-83.23M
Capital expenditure-$-160K-$-260K-$-330K-$-110K-$-70K
Free cash flow-$-85.97M-$-85.03M-$-71.16M-$-65.26M-$-83.3M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Immunic, Inc.

        Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.

        CEO
        Erik Lundgren
        Employees
        92
        Beta
        1.38

        Explore

        Frequently asked questions

        What is the intrinsic value of Immunic, Inc. (IMUX)?

        InvestorsCraft does not currently publish an intrinsic value for IMUX. How the IC value is calculated.

        Is IMUX undervalued?

        InvestorsCraft does not publish an undervaluation signal for IMUX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.